| 1 |
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019 [EB/OL].
URL
|
| 2 |
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [J]. Clin Infect Dis, 2011, 52(3): e18-55.
|
| 3 |
Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis [J]. Clin Infect Dis, 2017, 64(6): e34-e65.
|
| 4 |
Quagliarello VJ, Ma A, Stukenbrok H, et al. Ultrastructural localization of albumin transport across the cerebral microvasculature during experimental meningitis in the rat [J]. J Exp Med, 1991, 174(3): 657-672.
|
| 5 |
Scheld WM, Dacey RG, Winn HR, et al.Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone [J]. J Clin Invest, 1980, 66(2): 243-253.
|
| 6 |
von Wedel-Parlow M, Wolte P, Galla HJ. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro [J]. J Neurochem, 2009, 111(1): 111-118.
|
| 7 |
Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections [J]. Clin Microbiol Rev, 2010, 23(4): 858-883.
|
| 8 |
Ziai WC, Lewin JJ. Improving the role of intraventricular antimicrobial agents in the management of meningitis [J]. Curr Opin Neurol, 2009, 22(3): 277-282.
|
| 9 |
Cruciani M, Navarra A, Di Perri G, et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections [J]. Clin Infect Dis, 1992, 15(2): 285-289.
|
| 10 |
Erritouni M, Ktaich N, Rahal JJ, et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis [J]. Case Rep Med, 2012, 2012: 593578.
|
| 11 |
Mueller SW, Kiser TH, Anderson TA, et al. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium [J]. Ann Pharmacother, 2012, 46(12): e35.
|
| 12 |
Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP [J]. Semin Respir Crit Care Med, 2009, 30(1): 3-9.
|
| 13 |
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [J]. Clin Infect Dis, 2016, 63(5): e61-e111.
|
| 14 |
Lodise TP, Drusano GL, Butterfield JM, et al. Penetration of vancomycin into epithelial lining fluid in healthy volunteers [J]. Antimicrob Agents Chemother, 2011, 55(12): 5507-5511.
|
| 15 |
Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia [J]. Intensive Care Med, 2006, 32(5): 775-779.
|
| 16 |
Conte JEJr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid [J]. Antimicrob Agents Chemother, 2002, 46(5): 1475-1480.
|
| 17 |
Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia [J]. Crit Care Med, 2005, 33(7): 1529-1533.
|
| 18 |
Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin [J]. Intensive Care Med, 2004, 30(3): 388-394.
|
| 19 |
Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study [J]. Crit Care, 2014, 18(3): R118.
|
| 20 |
Pinholt M, Ostergaard C, Arpi M, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006-2009: a population-based cohort study [J]. Clin Microbiol Infect, 2014, 20(2): 145-151.
|
| 21 |
Bishara J, Goldberg E, Leibovici L, et al. Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia [J]. Int J Infect Dis, 2012, 16(6): e457-463.
|
| 22 |
Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis [J]. Clin Infect Dis, 2003, 36(1): 53-59.
|
| 23 |
Saliba P, Hornero A, Cuervo G, et al. Mortality risk factors among non-ICU patients with nosocomial vascular catheter-related bloodstream infections: a prospective cohort study [J]. J Hosp Infect, 2018, 99(1): 48-54.
|
| 24 |
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America [J]. Clin Infect Dis, 2009, 49(1): 1-45.
|
| 25 |
Mermel LA, Farr BM, Sherertz RJ, et al; Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheter-related infections [J]. Clin Infect Dis, 2001, 32(9): 1249-1272.
|
| 26 |
Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations [J]. Chest, 2012, 142(1): 30-39.
|
| 27 |
He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of Vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society [J]. Clin Infect Dis 2020, 71(Suppl 4): S363-S371.
|
| 28 |
Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis [J]. J Antimicrob Chemother, 2012, 67(1): 17-24.
|
| 29 |
Hanrahan T, Whitehouse T, Lipman J, et al. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion [J]. Int J Antimicrob Agents, 2015, 46(3): 249-253.
|
| 30 |
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists [J]. Am J Health Syst Pharm, 2020, 77(11): 835-864.
|
| 31 |
黄仲义, 肖永红, 张菁, 等. 万古霉素临床应用中国专家共识(2011版) [J]. 中国新药与临床杂志, 2011, 30(8): 561-573.
|
| 32 |
Ariano RE, Fine A, Sitar DS, et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis [J]. Am J Kidney Dis, 2005, 46(4): 681-687.
|
| 33 |
Freitas FM, Zamoner W, Reis PFD, et al. Vancomycin for dialytic therapy in critically ill patients: Analysis of its reduction and the factors associated with subtherapeutic concentrations [J]. Int J Environ Res Public Health, 2020, 17(18): 6861.
|
| 34 |
Rider TR, Silinskie KM, Hite MS, et al. Pharmacokinetics of Vancomycin in critically ill patients undergoing sustained low-efficiency dialysis [J]. Pharmacotherapy, 2020, 40(10): 1036-1041.
|
| 35 |
Allawati H, Dallas L, Nair S, et al. A pharmacokinetic study comparing the clearance of Vancomycin during haemodialysis using medium cut-off membrane (theranova) and high-flux membranes (revaclear) [J]. Toxins (Basel), 2020, 12(5): 317.
|
| 36 |
Lewis SJ, Mueller BA. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation [J]. SAGE Open Med, 2018, 6: 2050312118773257.
|
| 37 |
Launay-Vacher V, Izzedine H, Mercadal L, et al. Clinical review: use of vancomycin in haemodialysis patients [J]. Crit Care, 2002, 6(4): 313-316.
|
| 38 |
Ponce D, Zamoner W, Freitas FM, et al. Vancomycin removal during high-volume peritoneal dialysis in acute kidney injury patients: A prospective cohort clinical study [J]. Kidney Int Rep, 2019, 4(1): 112-118.
|
| 39 |
Park SJ, Yang JH, Park HJ, et al. Trough concentrations of vancomycin in patients undergoing extracorporeal membrane oxygenation [J]. PLoS One, 2015, 10(11): e0141016.
|
| 40 |
Donadello K, Roberts JA, Cristallini S, et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study [J]. Crit Care, 2014, 18(6): 632.
|
| 41 |
Cristallini S, Hites M, Kabtouri H, et al. New regimen for continuous infusion of Vancomycin in critically ill patients [J]. Antimicrob Agents Chemother, 2016, 60(8): 4750-4756.
|